Gareth Hughes

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 160 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont et al. · Journal of Medicinal Chemistry · 2022 · 56 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

Darren A.E. Cross, Sue Ashton, Caroline A. Nebhan et al. · Molecular Cancer Therapeutics · 2013 · 19 citations

Medicine, Oncology, Pharmacology +14

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

Sylvie M. Guichard, Zoë Howard, Dan Heathcote et al. · Cancer Research · 2012 · 17 citations

Medicine, Oncology, Pharmacology +13